New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - siltuximab 100mg;  ;   - powder for infusion concentrate - 100 mg - active: siltuximab 100mg     excipient: histidine polysorbate 80 sucrose - sylvant is indicated for the treatment of adult patients with multicentric castleman's disease (mcd) who are human immunodeficiency virus (hiv) negative and human herpesvirus-8 (hhv-8) negative.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - siltuximab - powder for solution for infusion - 100mg

Israel - English - Ministry of Health

medison pharma ltd - siltuximab - powder for concentrate for solution for infusion - siltuximab 100 mg - siltuximab - sylvant is indicated for the treatment of adult patients with multicentric castleman’s disease (mcd) who are human immunodeficiency virus (hiv) negative and human herpesvirus-8 (hhv-8) negative.

United States - English - NLM (National Library of Medicine)

janssen biotech, inc. - siltuximab (unii: t4h8fma7im) (siltuximab - unii:t4h8fma7im) - siltuximab 100 mg - sylvant is indicated for the treatment of patients with multicentric castleman's disease (mcd) who are human immunodeficiency virus (hiv) negative and human herpesvirus-8 (hhv-8) negative. limitations of use sylvant was not studied in patients with mcd who are hiv positive or hhv-8 positive because sylvant did not bind to virally produced il-6 in a nonclinical study. severe hypersensitivity reaction to siltuximab or any of the excipients in sylvant [see warnings and precautions (5.3)] . hypersensitivity reactions, including anaphylactic reaction, hypersensitivity, and drug hypersensitivity have been reported in patients treated with siltuximab. pregnancy category c risk-summary there are no adequate or well-controlled studies in pregnant women. in animal reproduction studies, administration of a human antibody to il-6 to pregnant cynomolgus monkeys caused decreases in globulin levels in pregnant animals and in the offspring. siltuximab crossed the placenta in monkeys. infants born to pregnant women treated wi

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - siltuximab, quantity: 100 mg - injection, powder for - excipient ingredients: histidine; polysorbate 80; sucrose - sylvant is indicated for the treatment of patients with multicentric castleman's disease (mcd) who are human immunodeficiency virus (hiv) negative and human herpesvirus-8 (hhv-8) negative.

Canada - English - Health Canada

eusa pharma (uk) limited - siltuximab - powder for solution - 100mg - siltuximab 100mg - immunosuppressive agents

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - siltuximab, quantity: 400 mg - injection, powder for - excipient ingredients: polysorbate 80; sucrose; histidine - sylvant is indicated for the treatment of patients with multicentric castleman's disease (mcd) who are human immunodeficiency virus (hiv) negative and human herpesvirus-8 (hhv-8) negative.

European Union - English - EMA (European Medicines Agency)

recordati netherlands b.v. - siltuximab - giant lymph node hyperplasia - immunosuppressants - sylvant is indicated for the treatment of adult patients with multicentric castleman’s disease (mcd who are human immunodeficiency virus (hiv) negative and human herpesvirus-8 (hhv-8) negative.,

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

link healthcare sdn. bhd. - siltuximab -

Philippines - English - FDA (Food And Drug Administration)

zuellig pharma corporation; distributor: zuellig pharma corporation - siltuximab - powder for concentrate for solution for infusion - 100 mg